Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ASXC NASDAQ:DRIO NASDAQ:MGRM NASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASXCAsensus Surgical$0.35$0.35$0.17▼$0.40$94.74M1.372.03 million shsN/ADRIODarioHealth$0.69-2.0%$0.70$0.50▼$1.55$30.50M1.55289,290 shs188,214 shsMGRMMonogram Orthopaedics$5.67-2.1%$3.07$1.92▼$6.02$202.35M0.59315,852 shs279,846 shsNPCENeuroPace$9.06-0.2%$12.33$5.45▼$18.98$297.16M1.93188,032 shs132,242 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASXCAsensus Surgical0.00%0.00%0.00%0.00%+3.67%DRIODarioHealth-2.00%-4.59%-4.71%-8.53%-45.98%MGRMMonogram Orthopaedics-2.07%+72.34%+93.52%+110.00%+160.09%NPCENeuroPace-0.22%-4.83%-14.53%-16.03%+20.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASXCAsensus SurgicalN/AN/AN/AN/AN/AN/AN/AN/ADRIODarioHealth1.3718 of 5 stars3.30.00.00.00.60.81.3MGRMMonogram Orthopaedics1.0445 of 5 stars1.82.00.00.02.31.70.6NPCENeuroPace2.9752 of 5 stars3.53.00.00.00.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASXCAsensus Surgical 0.00N/AN/AN/ADRIODarioHealth 2.67Moderate Buy$2.00191.55% UpsideMGRMMonogram Orthopaedics 3.50Strong Buy$5.40-4.76% DownsideNPCENeuroPace 3.00Buy$17.0087.64% UpsideCurrent Analyst Ratings BreakdownLatest ASXC, DRIO, MGRM, and NPCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASXCAsensus Surgical$8.58M11.04N/AN/A$0.13 per share2.68DRIODarioHealth$27.04M1.13N/AN/A$2.11 per share0.33MGRMMonogram Orthopaedics$370K546.93N/AN/A$0.42 per share13.50NPCENeuroPace$79.91M3.72N/AN/A$0.27 per share33.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASXCAsensus Surgical-$78.43M-$0.31N/AN/AN/A-902.25%-184.10%-114.75%N/ADRIODarioHealth-$42.75M-$0.56N/AN/AN/A-159.80%-65.81%-38.41%8/6/2025 (Estimated)MGRMMonogram Orthopaedics-$16.33M-$0.45N/AN/AN/AN/A-115.71%-92.75%8/13/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)Latest ASXC, DRIO, MGRM, and NPCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DRIODarioHealth-$0.11N/AN/AN/A$6.91 millionN/A8/13/2025Q2 2025MGRMMonogram Orthopaedics-$0.11N/AN/AN/AN/AN/A8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025MGRMMonogram Orthopaedics-$0.12-$0.10+$0.02-$0.10N/AN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASXCAsensus SurgicalN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASXCAsensus SurgicalN/A1.000.69DRIODarioHealth0.262.011.77MGRMMonogram OrthopaedicsN/A7.007.00NPCENeuroPace2.466.635.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASXCAsensus Surgical9.35%DRIODarioHealth33.39%MGRMMonogram Orthopaedics0.45%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipASXCAsensus Surgical2.87%DRIODarioHealth11.20%MGRMMonogram Orthopaedics28.10%NPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASXCAsensus Surgical170272.33 million264.52 millionNot OptionableDRIODarioHealth20044.46 million39.48 millionOptionableMGRMMonogram Orthopaedics2835.69 million25.66 millionNot OptionableNPCENeuroPace17032.80 million26.08 millionOptionableASXC, DRIO, MGRM, and NPCE HeadlinesRecent News About These CompaniesNeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles - Investing.comJuly 8, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...July 6, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 27, 2025 | prnewswire.comNeuroPace Announces Strategic CFO Transition - MorningstarJune 26, 2025 | morningstar.comMNeuroPace, Inc.: NeuroPace Announces Strategic CFO TransitionJune 25, 2025 | finanznachrichten.deINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - MorningstarJune 24, 2025 | morningstar.comMNeuroPace Announces Strategic CFO TransitionJune 24, 2025 | globenewswire.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 24, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 23, 2025 | globenewswire.comPalumbo Wealth Management LLC Has $567,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE)June 23, 2025 | marketbeat.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | gurufocus.comNPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law FirmJune 22, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. ...June 22, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 22, 2025 | prnewswire.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comNeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician SurveyJune 17, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 16, 2025 | accessnewswire.comANeuroPace’s SWOT analysis: med tech stock poised for growth amid challengesJune 14, 2025 | investing.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCEJune 13, 2025 | accessnewswire.comABronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to ConnectJune 13, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeASXC, DRIO, MGRM, and NPCE Company DescriptionsAsensus Surgical NYSEAMERICAN:ASXC$0.35 0.00 (0.00%) As of 08/22/2024Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.DarioHealth NASDAQ:DRIO$0.69 -0.01 (-2.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.70 +0.01 (+1.46%) As of 07/18/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Monogram Orthopaedics NASDAQ:MGRM$5.67 -0.12 (-2.07%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.72 +0.05 (+0.97%) As of 07/18/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.NeuroPace NASDAQ:NPCE$9.06 -0.02 (-0.22%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$9.12 +0.05 (+0.61%) As of 07/18/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
